ArticleCytotechnology2022

TLR agonist rMBP-NAP inhibits B16 melanoma tumor growth via induction of DCs maturation and T-cells cytotoxic response.

Jiaojiao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.